Johnson & Johnson (NYSE:JNJ) Shares Sold by Candriam Luxembourg S.C.A.

Candriam Luxembourg S.C.A. cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 5.0% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 395,606 shares of the company’s stock after selling 20,920 shares during the quarter. Johnson & Johnson comprises 0.6% of Candriam Luxembourg S.C.A.’s portfolio, making the stock its 28th biggest position. Candriam Luxembourg S.C.A.’s holdings in Johnson & Johnson were worth $58,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in JNJ. Krueger & Catalano Capital Partners LLC boosted its stake in shares of Johnson & Johnson by 6.9% in the fourth quarter. Krueger & Catalano Capital Partners LLC now owns 16,620 shares of the company’s stock worth $2,424,000 after buying an additional 1,072 shares during the last quarter. Vision Capital Management Inc. grew its holdings in Johnson & Johnson by 7.2% during the fourth quarter. Vision Capital Management Inc. now owns 24,995 shares of the company’s stock worth $3,646,000 after acquiring an additional 1,677 shares during the period. Aurora Investment Managers LLC. acquired a new stake in Johnson & Johnson during the fourth quarter worth about $2,009,000. Kiley Juergens Wealth Management LLC raised its position in Johnson & Johnson by 1.3% during the fourth quarter. Kiley Juergens Wealth Management LLC now owns 19,422 shares of the company’s stock valued at $2,833,000 after acquiring an additional 248 shares in the last quarter. Finally, Verus Financial Partners Inc. raised its position in Johnson & Johnson by 1.7% during the fourth quarter. Verus Financial Partners Inc. now owns 4,382 shares of the company’s stock valued at $639,000 after acquiring an additional 74 shares in the last quarter. Institutional investors and hedge funds own 67.36% of the company’s stock.

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 2,017 shares of the stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $141.07, for a total transaction of $284,538.19. Following the transaction, the executive vice president now directly owns 51,736 shares of the company’s stock, valued at $7,298,397.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Hubert Joly bought 5,000 shares of the company’s stock in a transaction dated Friday, December 13th. The stock was bought at an average price of $141.28 per share, for a total transaction of $706,400.00. Following the transaction, the director now owns 5,000 shares of the company’s stock, valued at $706,400. The disclosure for this purchase can be found here. Corporate insiders own 0.23% of the company’s stock.

Shares of Johnson & Johnson stock opened at $149.27 on Wednesday. The firm has a market cap of $392.60 billion, a PE ratio of 23.32, a P/E/G ratio of 2.40 and a beta of 0.71. Johnson & Johnson has a twelve month low of $125.00 and a twelve month high of $150.17. The company has a quick ratio of 1.00, a current ratio of 1.26 and a debt-to-equity ratio of 0.46. The business has a 50-day moving average price of $144.44 and a 200 day moving average price of $135.05.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 25th will be given a dividend of $0.95 per share. The ex-dividend date is Monday, February 24th. This represents a $3.80 dividend on an annualized basis and a yield of 2.55%. Johnson & Johnson’s dividend payout ratio is currently 46.45%.

A number of brokerages have issued reports on JNJ. Atlantic Securities upgraded Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research report on Wednesday, October 16th. Credit Suisse Group reaffirmed a “buy” rating and set a $163.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, December 31st. Wells Fargo & Co lifted their target price on shares of Johnson & Johnson from $155.00 to $165.00 and gave the company an “overweight” rating in a report on Thursday, January 9th. Sanford C. Bernstein raised shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 target price for the company in a report on Friday, October 11th. Finally, Cantor Fitzgerald assumed coverage on shares of Johnson & Johnson in a research note on Wednesday, November 27th. They issued an “overweight” rating and a $160.00 target price for the company. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $159.33.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Buy Rating

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.